NL-OMON36315已完成3 期
ong-Term, Open-Label, Safety Study of LY2216684 12 to 18 mg Once Daily as Adjunctive Treatment for Patients with Major Depressive Disorder Who are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment - LNBO 219-381
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Eli Lilly
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99(—)
入选标准
- •Male and female, adult outpatients aged *18 years who meet DSM-IV-TR diagnostic criteria for MDD as determined by clinical assessment by the Mini-International Neuropsychiatric Interview (MINI) and confirmed by the physician and who have experienced a partial treatment response to a course of SSRI treatment for at least 6 weeks with at least the last 4 consecutive weeks at a stable, optimized dose prior to Visit 2. Patients must have a score *16 on the GRID 17-Item Hamilton Rating Scale for Depression (GRID HAMD17) total score at Visit 1 and Visit 2. Patients will be determined to be partial responders by history, by the opinion of the investigator. Patients will also be required to have a rating indicating *75% improvement for their current SSRI treatment using the Massachusetts General Hospital Antidepressant Treatment Response Questionnaire (MGH-ATRQ) at Visit 1.
排除标准
- •Exclusion criteria include any additional DSM-IV-TR Axis I condition other than major depression that was considered the primary diagnosis within 1 year of Visit 1; other primary Axis I anxiety diagnosis within the past year (including panic disorder, obsessive-compulsive disorder [OCD], posttraumatic stress disorder [PTSD], generalized anxiety disorder [GAD], and social phobia, but excluding specific phobias); current or previous diagnosis of bipolar disorder, schizophrenia, or other psychotic disorder; have a serious or unstable medical condition; have any diagnosed medical condition that could be exacerbated by noradrenergic agents, including unstable hypertension, unstable heart disease, tachycardia or tachyarrhythmia, narrow-angle glaucoma, or history of urinary hesitation or retention; use of excluded concomitant medication; serious ideation/risk for harm to self or others; and pregnancy or breastfeeding status.
研究者
相似试验
进行中(未招募)
不适用
ot ApplicableMajor depressive disorder (MDD)MedDRA version: 14.0Level: LLTClassification code 10025453Term: Major depressive disorder NOSSystem Organ Class: 10037175 - Psychiatric disordersEUCTR2010-020726-18-LTEli Lilly and Company600
进行中(未招募)
不适用
ong-Term, Open-Label, Safety Study of LY2216684 12 to 18 mg Once Daily as Adjunctive Treatment for Patients with Major Depressive Disorder Who are Partial Responders to Selective Serotonin Reuptake Inhibitor TreatmentMajor depressive disorder (MDD)MedDRA version: 14.0Level: LLTClassification code 10025453Term: Major depressive disorder NOSSystem Organ Class: 10037175 - Psychiatric disordersEUCTR2010-020726-18-PTEli Lilly and Company600
招募中
3 期
ong-Term, Open-Label, Safety Study of LY2216684 12 to 18 mg Once Daily as Adjunctive Treatment for Adult Patients with Major Depressive Disorder Who were Partial Responders to Selective Serotonin Reuptake Inhibitor TreatmentMajor Depressive DisorderJPRN-jRCT2080221483Eli Lilly Japan K.K.
进行中(未招募)
1 期
ong-Term, Open-Label, Safety Study of LY2216684 12 to 18 mg Once Daily as Adjunctive Treatment for Patients with Major Depressive Disorder Who are Partial Responders to Selective Serotonin Reuptake Inhibitor TreatmentEUCTR2010-020726-18-NLEli Lilly and Company600
进行中(未招募)
不适用
A Long-Term Study in SchizophreniaMedDRA version: 14.1Level: PTClassification code 10039626Term: SchizophreniaSystem Organ Class: 10037175 - Psychiatric disordersSchizophreniaEUCTR2011-004327-13-ATEli Lilly and Company282
